RESUMO
Leukemia invades the bone marrow progressively and, through unknown mechanisms, outcompetes healthy hematopoiesis. Protein arginine methyltransferases 1 (PRMT1) are found in prokaryotes and eukaryotes cells. They are necessary for a number of biological processes and have been linked to several human diseases, including cancer. Small compounds that target PRMT1 have a significant impact on both functional research and clinical disease treatment. In fact, numerous PRMT1 inhibitors targeting the S-adenosyl-L-methionine binding region have been studied. Through topographical descriptors, quantitative structure-activity relationships (QSAR) were developed in order to identify the most effective PRMT1 inhibitors among 17 compounds. The model built using linear discriminant analysis allows us to accurately classify over 90% of the investigated active substances. Antileukemic activity is predicted using a multilinear regression analysis, and it can account for more than 56% of the variation. Both analyses are validated using an internal "leave some out" test. The developed model could be utilized in future preclinical experiments with novel drugs.
Assuntos
Leucemia , Neoplasias , Humanos , Relação Quantitativa Estrutura-Atividade , Proteína-Arginina N-Metiltransferases/metabolismo , Inibidores Enzimáticos/farmacologia , Leucemia/tratamento farmacológico , Proteínas Repressoras/metabolismoRESUMO
BACKGROUND: Philadelphia negative myeloproliferative neoplasms (Ph-MPN) are clonal disorders whose pathogenesis has been elucidated in recent years, creating diagnostic and prognostic algorithms. AIM: To study JAK2, CALR y MPL gene mutations in patients with Ph-MPN. MATERIALS AND METHODS: Descriptive cross-sectional observational study of patients with MPN (2015-2019), reviewing clinical, demographic and laboratory data. JAK2, CALR and MPL gene mutations were analyzed by RT-PCR. Results: We studied 72 patients. Fifty percent had essential thrombocythemia (ET), 26.4% had polycythemia vera (PV) and 23.6% had primary myelofibrosis (PM). Bone marrow biopsy was available in 76.5%. At diagnosis, the mean age was 65.5 years and 61% were symptomatic. A thrombotic event was the most frequent problem in 20% and 25% had splenomegaly. There were statistically significant differences in hematological parameters between the different MPNs. JAK2 V617F mutation was detected in 61.1%. Only 19 JAK2 V617F negative patients were available for CALR and MPL mutation studies, identifying 10 triple negative cases. Kaplan Meier curves showed a median survival of 88 months, being similar in the three MPNs. Causes of death in 20 patients were thrombotic complications in 30%, disease progression in 25%, infection in 20%, other neoplasms in 15% and other causes in 10%. CONCLUSIONS: The presentation and frequency of JAK2 V617F, CALR and MPL mutations in our cohort was similar to those reported in other studies for ET and PM. JAK2 V617F mutation was lower for PV. No significant differences between the three MPNs were observed for overall survival. We could not assess the prognostic value of the mutations.
Assuntos
Humanos , Idoso de 80 Anos ou mais , Policitemia Vera/genética , Trombocitemia Essencial/diagnóstico , Trombocitemia Essencial/genética , Transtornos Mieloproliferativos/genética , Chile , Estudos Transversais , Hospitais Públicos , MutaçãoRESUMO
Background: Primary erythrocytosis is a rare myeloproliferative disorder in dogs and cats characterized by an autonomous proliferation of erythroid precursors in the bone marrow, with low to normal serum erythropoietin concentration, resulting in elevated red blood cell count, hematocrit and hemoglobin concentration. Clinical signs are associated with increased blood volume and viscosity, and may include erythema, hyperemic mucous membranes and neurological signs such as seizures and ataxia. In veterinary medicine, the diagnosis should be made by exclusion of secondary or relative causes, after complementary exams. This report aims to describe a case of primary erythrocytosis in a bitch. Case: A 4-year-old mixed-breed bitch was referred to the Veterinary Medical Teaching Hospital from UFRGS with 3 convulsive episodes related by the owner. A previous abdominal ultrasonography revealed splenomegaly and the electrocardiogram showed no abnormalities. No alterations were observed at the physical examination. The laboratorial blood tests demonstrated a persistent erythrocytosis, with high hematocrit, hemoglobin and red blood cells count, thrombocytopenia and neutropenia, and total plasmatic protein within the reference interval. The bone marrow cytology revealed reduced cellularity, normal myeloid:erythroid ratio, erythroid hyperplasia, mild myeloid hyperplasia and moderate myelofibrosis. The serum erythropoietin measurement was within the reference range, and the blood gas analysis detected a slight decrease in partial oxygen pressure. Therefore, no evidence of secondary conditions was observed and the diagnosis of primary erythrocytosis could be made. Discussion: Since there is no definitive method, the diagnosis of primary erythrocytosis could be based on the exclusion of all secondary and relative causes of erythrocytosis. The absence of clinical signs of dehydration and high serum albumin levels were findings that conduced for the exclusion of the relative form of the disturbance. The echocardiography and the abdominal ultrasonography ruled out any cardiopulmonary condition or kidney neoplasm, the most common causes of absolute secondary erythrocytosis. The persistently high hematocrit levels and red blood cell counts are significant for the suspicion of primary erythrocytosis, although thrombocytopenia and neutropenia are not commonly reported. The clinical signs of seizure were correlated with increased blood viscosity and reduced blood flow at the central nervous system. The blood gas analysis discarded the occurrence of systemic hypoxia, and the normal levels of erythropoietin gives higher evidence of the occurrence of an autonomous proliferation of the erythroid precursors within the bone marrow. The bone marrow cytology confirmed erythroid hyperplasia and the reduced cellularity that could be attributed to myelofibrosis. Myelofibrosis was described in humans with polycythemia vera, but there are no reports in veterinary, and this occurrence must be elucidated. An identical mutation in the JAK2 gene was observed in humans with polycythemia vera and dogs with primary erythrocytosis, and occurs in more than 50% of humans with myelofibrosis. Further investigations are necessary for veterinary medicine. In conclusion, the systematic approach of all organic systems and the assessment of complementary exams are necessary for the diagnostic of primary erythrocytosis in dogs. This condition should be considered in the differential diagnosis of any erythrocytosis, considering the guarded prognosis of this hematologic disorder.
Assuntos
Animais , Feminino , Cães , Policitemia/veterinária , Eritropoetina/análise , Mielofibrose Primária/veterinária , Esplenomegalia/veterinária , Ultrassonografia/veterináriaRESUMO
Toll-like receptors (TLRs) are a family of transmembrane receptors whose signaling control cellular processes of cell proliferation, survival, apoptosis, angiogenesis, remodeling, and repair of tissues. Polymorphisms in TLR genes can change the balance between pro and anti-inflammatory cytokines, modulating the risk of infection, chronic inflammation, and cancer. Although many studies have demonstrated the direct involvement of TLR signaling in the benefit of tumor cells in certain cancers, little is known about the influence of these gene polymorphisms on myeloproliferative neoplasms (MPNs). In this context, the objective of the study was to investigate a possible association between the TLR polymorphisms and the development of MPNs. 167 patients diagnosed with MPN and 222 healthy controls from the same region were evaluated. Genomic DNA was extracted and the TLR2 (rs5743708), TLR4 (rs4986790, rs4986791), TLR9 (rs5743836, rs187084) and JAK2V617F polymorphisms were genotyped by PCR-RFLP. The statistical analysis was performed by OpenEpi and SNPstat software. The JAK2V617F mutation was found in 68.32% of patients. TLR9-1486C/T CT genotype was less frequent in patients with polycythemia vera (PV) (OR 0.39, 95% CI 0.20-0.78, P = 0.025). When haplotype frequencies were analyzed, -1237T/-1486C (TLR9) was also less frequent in men (OR 0.58, 95% CI 0.36-0.94) and JAK negative men patients (OR 0.43, 95% CI 0.21-0.88). We can infer that the TLR9-1486 CT genotype could be associated with protection for PV and the TLR9-1237T/-1486C haplotype, protection for men, as well as for JAK negative men patients with MPN. There were no associations between TLR2 and TLR4 gene polymorphisms and MPN.
Assuntos
Neoplasias da Medula Óssea/genética , Janus Quinase 2/genética , Receptor Toll-Like 9/genética , Receptores Toll-Like/genética , Adulto , Idoso , Neoplasias da Medula Óssea/metabolismo , Feminino , Haplótipos/genética , Humanos , Janus Quinase 2/metabolismo , Masculino , Pessoa de Meia-Idade , Transtornos Mieloproliferativos/genética , Policitemia Vera/genética , Polimorfismo de Nucleotídeo Único/genética , Mielofibrose Primária/genética , Trombocitemia Essencial/genética , Receptor 2 Toll-Like/genética , Receptor 2 Toll-Like/metabolismo , Receptor 4 Toll-Like/genética , Receptor 4 Toll-Like/metabolismo , Receptor Toll-Like 9/metabolismo , Receptores Toll-Like/metabolismoRESUMO
ABSTRACT Background: The classical BCR-ABL1-negative myeloproliferative neoplasms (MPNs) are Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF). In developing countries, there are few reports that truly reveal the clinical setting of these patients. Therefore, we aimed to characterize a single center MPN population with a special focus on the correct diagnosis based on the recent review of the WHO criteria for the diagnosis of myeloid neoplasms. Methods: This retrospective study analyzed data from medical records of patients with classical BCR-ABL1-negative MPNs diagnosed from January 1997 to October 2017 and followed at the University Hospital of Ribeirão Preto Medical School. Results: A total of 162 patients were assessed, 61 with PV, 50 with ET, and 51 with PMF. The mutational status analysis revealed that 113 (69.3%) harbored the JAK2V617F mutation, 23 (14.1%), the CALR mutation, and 12 (7.4%) had a triple-negative status. None of the patients were found to have mutations on the thrombopoietin receptor gene (MPL), including some ET and PMF patients who were not tested. Among the PV patients, 57 (93.5%) were positive for the JAK2V617F mutation, one (1.6%) presented an in-frame deletion JAK2 exon 12 mutation and one (1.6%) presented a missense JAK2 exon 9 mutation, not previously described. The overall survival was lower in the triple-negative patients with PMF, when compared to the JAK2V617F or CALR-mutated (p= 0.002). Conclusion: The frequency of somatic mutations and survival in our cohort, stratified according to the respective disease, was consistent with the literature data, despite some limitations. Further prospective epidemiological studies of MPN cohorts are encouraged in developing countries.
Assuntos
Humanos , Masculino , Adulto , Pessoa de Meia-Idade , Idoso , Idoso de 80 Anos ou mais , Policitemia Vera , Leucemia Mieloide Crônica Atípica BCR-ABL Negativa , Mielofibrose Primária , Trombocitemia Essencial , Transtornos MieloproliferativosRESUMO
Resumen El pioderma gangrenoso ampolloso fue descrito por primera vez en 1972. Se presenta el caso de una paciente con pioderma gangrenoso asociado a una recaída de leucemia mieloide aguda y se hace una revisión de la literatura sobre el tema.
Abstract Bullous pyoderma gangrenosum was first described by Perry in 1972. We present a case of a patient with paraneoplastic pyoderma gangrenosum associated to relapse of an acute myelogenous leukemia and we review the literature on pyoderma gangrenosum.
RESUMO
BACKGROUND: The classical BCR-ABL1-negative myeloproliferative neoplasms (MPNs) are Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF). In developing countries, there are few reports that truly reveal the clinical setting of these patients. Therefore, we aimed to characterize a single center MPN population with a special focus on the correct diagnosis based on the recent review of the WHO criteria for the diagnosis of myeloid neoplasms. METHODS: This retrospective study analyzed data from medical records of patients with classical BCR-ABL1-negative MPNs diagnosed from January 1997 to October 2017 and followed at the University Hospital of Ribeirão Preto Medical School. RESULTS: A total of 162 patients were assessed, 61 with PV, 50 with ET, and 51 with PMF. The mutational status analysis revealed that 113 (69.3%) harbored the JAK2V617F mutation, 23 (14.1%), the CALR mutation, and 12 (7.4%) had a triple-negative status. None of the patients were found to have mutations on the thrombopoietin receptor gene (MPL), including some ET and PMF patients who were not tested. Among the PV patients, 57 (93.5%) were positive for the JAK2V617F mutation, one (1.6%) presented an in-frame deletion JAK2 exon 12 mutation and one (1.6%) presented a missense JAK2 exon 9 mutation, not previously described. The overall survival was lower in the triple-negative patients with PMF, when compared to the JAK2V617F or CALR-mutated (pâ¯=â¯0.002). CONCLUSION: The frequency of somatic mutations and survival in our cohort, stratified according to the respective disease, was consistent with the literature data, despite some limitations. Further prospective epidemiological studies of MPN cohorts are encouraged in developing countries.
RESUMO
BACKGROUND: Research into Philadelphia-negative chronic myeloproliferative neoplasms is heterogeneous. In addition, no systematization of studies of polycythemia vera (PV), essential thrombocythemia (ET) or primary myelofibrosis (PMF) have been carried out. The objective of this review is to characterize studies on BCR-ABL1-negative chronic myeloproliferative neoplasms and to compare the frequency of JAK2, MPL and CALR mutations in PV, ET and PMF. METHOD: A systematic review of the scientific literature was conducted, as was meta-analysis with an ex-ante selection of protocol, according to phases of the PRISMA guide in three interdisciplinary databases. To guarantee reproducibility in the pursuit and retrieval of information, the reproducibility and methodological quality of the studies were evaluated by two researchers. RESULTS: Fifty-two studies were included, the majority having been carried out in the United States, China, Brazil and Europe. The frequency of the JAK2V617F mutation ranged from 46.7 to 100% in patients with PV, from 31.3 to 72.1% in patients with ET, and from 25.0 to 85.7% in those with PMF. The frequency of the MPL mutation was 0% in PV, from 0.9 to 12.5% in ET, and from 0 to 17.1% in PMF. The CALR mutation occurred at a frequency of 0.0% in PV, whereas in ET, it ranged from 12.6 to 50%, and in PMF, it ranged from 10 to 100%. The risk of this mutation presenting in PV is 3.0 times that found for ET and 4.0 times that found for PMF. CONCLUSION: Given the specificity and reported high frequencies of the JAK2V617F, MPL and CALR mutations in this group of neoplasms, the diagnosis of these diseases should not be made on clinical and hematological characteristics alone but should include genetic screening of patients.
Assuntos
Calreticulina/genética , Janus Quinase 2/genética , Taxa de Mutação , Policitemia Vera/genética , Mielofibrose Primária/genética , Receptores de Trombopoetina/genética , Trombocitemia Essencial/genética , Biomarcadores Tumorais/genética , Heterogeneidade Genética , Testes Genéticos , Humanos , Proteínas de Fusão Oncogênica/genética , Reprodutibilidade dos TestesRESUMO
Myelofibrosis (MF) is characterized by increased circulating hematopoietic progenitor cells (HPCs), abnormal cytokine levels, and the survival advantage of neoplastic progenitors over their normal counterparts, which leads to progressive disappearance of polyclonal hematopoiesis. CD47 is a surface glycoprotein with many functions, such as acting as a phagocytosis inhibitor of the expressing cell, that is increased in normal hematopoietic stem and progenitor cells mobilized into the blood and several human cancer-initiating cells, such as in acute myeloid leukemia. We compared CD47 expression in hematopoietic stem and progenitor cells of patients with MF and controls and found it to be decreased in progenitors of MF. Exposure of control HPCs to the cytokines transforming growth factor β and stromal-derived factor 1, which are important regulators of hematopoietic stem cell cycling and are overexpressed in patients with MF, did not modulate CD47 expression.
Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Idoso , Idoso de 80 Anos ou mais , Adulto Jovem , Células-Tronco Hematopoéticas/metabolismo , Antígeno CD47/metabolismo , Mielofibrose Primária/metabolismo , Estudos de Casos e Controles , Fator de Crescimento Transformador beta/metabolismo , Quimiocina CXCL12/metabolismo , Mielofibrose Primária/genéticaRESUMO
Abstract: Purpura is defined as a visible hemorrhage in the skin or mucosa, which is not evanescent upon pressure. Proper classification allows a better patient approach due to its multiple diagnoses. Purpuras can be categorized by size, morphology, and other characteristics. The course varies according to the etiology, as do the diagnostic approach and treatment. This review discusses pigmented purpuras and some cutaneous vascular occlusion syndromes.
Assuntos
Humanos , Transtornos da Pigmentação/diagnóstico , Púrpura/diagnóstico , Dermatopatias Vasculares/diagnóstico , Púrpura/etiologia , Púrpura/patologia , Pele/irrigação sanguínea , Síndrome , Calciofilaxia/patologia , Síndrome Antifosfolipídica/complicações , Síndrome Antifosfolipídica/patologia , Dermatopatias Vasculares/patologia , Diagnóstico Diferencial , Púrpura Fulminante/patologiaRESUMO
Resumen Objetivo: describir las características sociodemográflcas y los síntomas en pacientes colombianos con neoplasias mieloproliferativas crónicas. Métodos: los autores utilizaron la información contenida en el ejercicio de validación de la escala de síntomas MPN-SAF TSS -myeloproliferative neoplasm symptom assessment form total symptom score-, la cual, a través de una metodología de encuesta en 62 pacientes diagnosticados con estas neoplasias a nivel nacional, aportó el insumo de análisis para alcanzar el objetivo de este estudio. Resultados: dentro de las características sociodemográflcas, la variable edad concentró el 59% de los pacientes incluidos en el estudio por encima de los 60 años con una media de 58,8 (DS 15,53). Se identifica una mayor frecuencia y severidad de los síntomas en pacientes con diagnóstico de policitemia vera, seguido de trombocitemia esencial y, por último, en pacientes con diagnóstico de mielofibrosis. La "fatiga" se manifestó en el 98,3% de los pacientes, siendo el principal síntoma registrado en la escala utilizada en este estudio. Conclusión: los pacientes en estudio presentaron una edad promedio de 59 años con una mayor proporción de mujeres (58%) y una escolaridad baja (40%). El total de síntomas referidos en la escala se presentaron en más del 70% de los pacientes, siendo los más frecuentes fatiga, saciedad temprana y problemas de concentración.
Abstract Objective: To describe the sociodemographic characteristics and symptoms in Colombian patients with chronic myeloproliferative neoplasms. Methods: The authors used the information contained in the validation exercise symptom scale MPN-SAF TSS -myeloproliferative neoplasm symptom assessment form the total symptom score-, which, through a survey methodology in 62 patients diagnosed with these malignancies level in Colombia, provided the input analysis to achieve the objective of this study. Results: Among the socio-demographic characteristics, the age variable accounted for 59% of the patients included in the study over 60 years, with a mean of 58.8 (SD 15.53). Increased frequency and severity of symptoms in patients diagnosed with polycythemia vera were identified, followed by essential thrombocythemia and finally in patients diagnosed with myelofibrosis. "Fatigue" was expressed in 98% of patients to be the main symptom registered on the scale used in this study. Conclusion: The patients in the study had a mean age of 59 years with a higher proportion of women by 58% and a low level of schooling of 40%. The total number of symptoms referred to in the scale occurred in more than 70% of the patients, being the most frequent fatigue, early satiety and concentration problems.
Resumo Objetivo: descrever as características sócio demográficas e os sintomas em pacientes colombianos com neoplasia mieloproliferativa crónica. Métodos: os autores utilizaram a informação contida no exercício de validação da escala de sintomas MPN-SAF TSS -myeloproliferative neoplasm symptom assessment form total symptom score-, a qual, através de uma metodologia de questionário em 62 pacientes diagnosticados com estas neoplasias a nível país, aportaram o insumo de análise para alcançar o objetivo deste estudo. Resultados: dentro das características sócio demográficas, a variável idade concentrou o 59% dos pacientes incluídos no estudo por cima dos 60 anos com uma média de 58,8 (DS 15,53); se identifica uma maior frequência e severidade dos sintomas, em pacientes com diagnóstico de policitemia vera, seguido de trombocitemia essencial e por último em pacientes com diagnósticos de mielofibrose. A "fatiga" se manifestou no 98,3% dos pacientes sendo o principal sintoma registrado na escala utilizada neste estudo. Conclusão: os pacientes em estudo apresentaram uma idade média de 59 anos com uma maior proporção de mulheres 58% e uma escolaridade baixa do 40; o total de sintomas referidos na escala se apresentaram em mais do 70% dos pacientes, sendo os mais frequentes a fatiga, saciedade precoce e problemas de concentração.
Assuntos
Humanos , Transtornos Mieloproliferativos , Sinais e Sintomas , Colômbia , Avaliação de SintomasRESUMO
Resumen Introducción y objetivos: las neoplasias mieloproliferativas crónicas (NMPC) son relativamente raras, con incidencias que varían entre 0.47-1.03/100 000 habitantes. Se presenta el primer informe del trabajo del registro colombiano de NMPC, cuyo objetivo es describir las características clínicas de estos pacientes en nuestro país. Material y métodos: estudio descriptivo observacional, multicéntrico, retrospectivo y prospectivo en ocho centros del país, de abril de 2013 a diciembre de 2014. Las variables cualitativas se presentan con frecuencias absolutas y relativas; y las cuantitativas se resumen en medidas de tendencia central y dispersión. Resultados: once centros fueron aprobados, ocho ingresaron pacientes. En los primeros 179 casos reportados, 50% eran hombres, la edad promedio al diagnóstico 58.7 años (rango 19-92). Noventa y tres muestran trombocitemia esencial (TE); 55, policitemia vera (PV); y 31, mielofibrosis (MF). El 41% tenía esplenomegalia al diagnóstico; el 20% tuvo complicaciones trombóticas; y 12.85%, sangrado. Sólo en 57.5% se realizó JAK; de ellos, en 53.5% fue positivo, en especial sólo 60% de las PV. El 8% de los casos no tenía estudio de médula ósea, el 29.3% tiene algún grado de fibrosis. El hallazgo más frecuente fue hiperplasia megacariocítica en 59.78%. Más de 50% de pacientes estaban sintomáticos al diagnóstico. Sólo el 11% no recibió tratamiento farmacológico; los más frecuentes fueron hidroxiurea en 149 casos y ASA en 79. Con promedio de seguimiento de 52.6 meses; el 97.21% de los pacientes están vivos. Conclusiones: los hallazgos sugieren que algunas características de las NMPC podrían ser diferentes a lo reportado en otras series, lo que valida la importancia del esfuerzo de recoger información local.
Abstract Introduction and objectives: chronic MPNs are relatively rare, with incidences varying between 0.47-1.03 / 100 000 inhabitants. The first report of the work of the Colombian registry of chronic MPNs, whose objective is to describe the clinical characteristics of these patients in our country, is presented. Materials and methods: descriptive observational, multicenter, retrospective and prospective study in eight centers of the country, from April 2013 to December 2014. Qualitative variables are presented with absolute and relative frequencies, and the quantitative ones are summarized in measures of central tendency and dispersion. Results: eleven centers were approved; 8 admitted patients. In the first 179 cases reported, 50% were men; the average age at diagnosis was 58.7 years (range 19-92). Ninety-three present essential thrombocythemia (ET); 55, polycythemia vera (PV); and 31, myelofibrosis (MF). 41% had splenomegaly at diagnosis; 20% had thrombotic complications, and 12.85%, bleeding. JAK was performed in only 57.5%. Of them, in 53.5% was positive, especially in only 60% of the PV. 8% of the cases had no bone marrow study; 29.3% had some degree of fibrosis. The most frequent finding was megakaryocytic hyperplasia in 59.78%. More than 50% of patients were symptomatic at diagnosis. Only 11% did not receive pharmacological treatment, being the most frequent hydroxyurea in 149 cases and ASA in 79, with an average follow-up of 52.6 months. 97.21% of patients are alive. Conclusions: the findings suggest that some characteristics of chronic MPNs could be different from those reported in other series, which validates the importance of the effort to collect local information.
Assuntos
Humanos , Masculino , Feminino , Transtornos Mieloproliferativos , Policitemia Vera , Sistema de Registros , Mielofibrose Primária , Trombocitemia Essencial , MutaçãoRESUMO
Resumen Objetivo: Validar en Colombia la escala abreviada de síntomas representativos de neoplasias mieloproliferativas para su posterior uso en investigación y aplicación en el ámbito clínico. Materiales y métodos: Se realizó la adaptación transcultural de la escala MPN-SAF-TSS (por sus siglas en inglés: Mieloproliferative Neoplasm Symptom Assesment Form-Total Sympton Score) a español y al contexto colombiano, con análisis estadísticos de validez y confiabilidad con un tamaño de muestra determinado para cada propiedad psicométrica. Resultados: Con base en las propiedades psicométricas se logró verificar la confiabilidad y la estructura interna de la escala con alfa de Cronbach de 0,8552, lo que denota una buena consistencia interna; se obtuvo un coeficiente de correlación de concordancia de Lin de 0,765 que muestra una buena confiabilidad. El análisis factorial mostró múltiples valores de coeficiente de correlación por encima de 0,3, lo que indica que las variables de la escala miden factores comunes; la validez de criterio concurrente determina que la escala mide lo que debe medir con un adecuado coeficiente de correlación de Spearman de -0,71 y -0,73 al confrontarla con las escalas FACIT-Fatigue y Fact-Lym respectivamente. Conclusión: La escala MPN-SAF-TSS adaptada a español y al contexto colombiano es un instrumento válido para la evaluación de síntomas en pacientes con neoplasias mieloproliferativas y puede ser utilizado en la práctica clínica o en estudios clínicos por sus adecuadas propiedades psicométricas.
Abstract Objective: To validate in Colombia the abbreviated scale of representative symptoms of myeloproliferative neoplasms, for further use in research and for application in the clinical setting. Materials and methods: A cross-cultural adaptation of the MPN-SAF TSS-scale (mieloproliferative neoplasm symptom assessment form total symptom score) to Colombian Spanish using statistical validity and reliability analysis with a specific sample size for each psychometric property. Results. Based on the psychometric properties, the verification of reliability and internal structure with a Cronbach's alpha scale of 0.8552 was achieved, denoting good internal consistency. A Lin's concordance correlation coefficient of 0.765 was obtained, showing good reliability; factor analysis showed multiple correlation coefficient values above 0.3, indicating that the scale variables measure common factors. Concurrent validity determines that the scale measures what it should measure with an adequate Spearman correlation coefficient of -0.71 and -0.73 when confronted with the FACIT-Fatigue and Fact-Lym scales, respectively. Conclusion: The MPN-SAF-TSS scale adapted to Colombian Spanish is a valid assessment instrument for symptoms in patients with myeloproliferative neoplasms and can be used in clinical practice or trials due to its adequate psychometric properties.
Resumo Objetivo: Validar na Colômbia, a escala abreviada de sintomas representativos de neoplasias mielo-proliferativas, para u seu posterior uso em investigação e a sua aplicação no âmbito clínico. Materiais e métodos: Realizou-se a adaptação transcultural da escala MPN-SAF-TSS (pelas suas siglas em inglês mieloproliferative neoplasm symptom assesment form total sympton score) ao espanhol colombiano, com análises estadísticas de validez e confiabilidade com um tamanho de amostra determinado para cada propriedade psicométrica. Resultados: Com base nas propriedades psicomé-tricas conseguiu-se verificar a confiabilidade e a estrutura interna da escala com alfa de Cronbach de 0,8552, o que denota uma boa consistência interna; se obteve um coeficiente de correlação de concordância de Lin de 0,765 mostrando uma boa confiabilidade; a análise fatorial mostrou múltiplos valores de coeficiente de correlação por acima de 0.3 indicando que as variáveis da escala medem fatores comuns, a validez de critério concorrente determina que a escala mede o que deve medir, com um adequado coeficiente de correlação de Spearman de -0,71 e -0,73 ao confrontá-la com as escalas FACIT-Fatigue e Fact-Lym respectivamente. Conclusão: A escala MPN-SAF TSS adaptada ao espanhol colombiano, é um instrumento válido para a avaliação de sintomas em pacientes com neoplasias mieloproliferativas e pode ser utilizado na prática clínica ou em estudos clínicos pelas suas adequadas propriedades psicométricas.
Assuntos
Humanos , Transtornos Mieloproliferativos , Qualidade de Vida , Colômbia , Avaliação de Sintomas , NeoplasiasRESUMO
Primary myelofibrosis is a Philadelphia-negative myeloproliferative neoplasm characterized by clonal myeloid expansion, followed by progressive fibrous connective tissue deposition in the bone marrow, resulting in bone marrow failure. Clonal evolution can also occur, with an increased risk of transformation to acute myeloid leukemia. In addition, disabling constitutional symptoms secondary to the high circulating levels of proinflammatory cytokines and hepatosplenomegaly frequently impair quality of life. Herein the main current treatment options for primary myelofibrosis patients are discussed, contemplating disease-modifying therapeutics in addition to palliative measures, in an individualized patient-based approach.
RESUMO
The classical chromosome Philadelphia-negative myeloproliferative neoplasms (MPNs) are a group of disorders that share clinical, hematological, and histological features. Proinflammatory cytokines such as tumor necrosis factor-α (TNF-α) are elevated in patients with MPN. The aim of this study was to verify the association between the polymorphisms of TNF gene (-308G/A and -238 G/A) in BCR-ABL-negative MPN in our population. Blood samples obtained from MPN patients were genotyped for the JAK2V617F mutation and both TNF polymorphisms using PCR-RFLP. Thirty three (26.8%) patients with polycythemia vera (PV), 35 (28.7%) essential thrombocythemia (ET), 22 (17.7%) primary myelofibrosis (PMF), and 33 (26.8%) with unclassifiable MPN (MPNu) were included in the study. The JAK2 V617F mutation was detected in 94 (76.42%) patients. Were observed a significant increase on the frequency of the TNF-238 GA genotype in MPN patients compared to controls (OR=2.21, 95% CI=1.02-4.80, P<0.04). The distribution of the genotypes and allelic frequencies of TNF-308 was significantly different among the MPNs, JAK2V617F positive, PV and PMF, and controls. Our data has demonstrated that the polymorphisms on TNF-238 GA, TNF-308 GA were associated to MPN development in this population, triggered by JAK2 V617F mutation.
Assuntos
Janus Quinase 2/genética , Leucemia Mieloide Crônica Atípica BCR-ABL Negativa/genética , Policitemia Vera/genética , Polimorfismo Genético , Mielofibrose Primária/genética , Trombocitemia Essencial/genética , Fator de Necrose Tumoral alfa/genética , Adulto , Idoso , Alelos , Brasil , Estudos de Casos e Controles , Análise Mutacional de DNA , Feminino , Expressão Gênica , Predisposição Genética para Doença , Humanos , Leucemia Mieloide Crônica Atípica BCR-ABL Negativa/diagnóstico , Leucemia Mieloide Crônica Atípica BCR-ABL Negativa/patologia , Masculino , Pessoa de Meia-Idade , Policitemia Vera/diagnóstico , Policitemia Vera/patologia , Mielofibrose Primária/diagnóstico , Mielofibrose Primária/patologia , Regiões Promotoras Genéticas , Trombocitemia Essencial/diagnóstico , Trombocitemia Essencial/patologiaRESUMO
Primary myelofibrosis is a Philadelphia-negative myeloproliferative neoplasm characterized by clonal myeloid expansion, followed by progressive fibrous connective tissue deposition in the bone marrow, resulting in bone marrow failure. Clonal evolution can also occur, with an increased risk of transformation to acute myeloid leukemia. In addition, disabling constitutional symptoms secondary to the high circulating levels of proinflammatory cytokines and hepatosplenomegaly frequently impair quality of life. Herein the main current treatment options for primary myelofibrosis patients are discussed, contemplating disease-modifying therapeutics in addition to palliative measures, in an individualized patient-based approach
Assuntos
Humanos , Janus Quinase 2 , Mielofibrose Primária , Transtornos MieloproliferativosRESUMO
Acute erythroid leukemia (AML M6) is a hematopoietic neoplasm frequently described in cats and mice, rarely in other animal species. This report describes a case of AML M6 in a yearling Thoroughbred filly. Clinically the horse presented marked pale mucous membranes and exercise intolerance. In addition, the owner and referring veterinarian reported a 30-day history of progressive weight loss. The CBC revealed severe anemia and leukopenia by neutropenia. Cytology evaluation obtained from bone marrow fine needle aspirates evidenced inversion of the myeloid: erythroid ratio (0.2), with 48% of the nucleated cells corresponding to rubriblasts. In addition to the gross evidence of anemia, necropsy findings consisted of splenomegaly and lymphadenomegaly. The diagnosis of AML M6B was confirmed histologically due to splenomegaly and lymphadenomegaly, secondary to neoplastic metastasization.
Leucemia eritroide aguda (LMA M6) é um neoplasia hematopoiética descrita com frequência em gatos e camundongos, mas raramente nas demais espécies de animais. Esse relato descreve um caso dessa doença em um equino, fêmea, Puro Sangue Inglês de um ano de idade. Clinicamente, o equino apresentou acentuada palidez das mucosas, intolerância ao exercício e o proprietário relatava emagrecimento progressivo. No hemograma, foi observada anemia grave e leucopenia por neutropenia. No mielograma, havia inversão da relação mieloide:eritroide (0,2) e 48% das células nucleadas da medula óssea correspondiam a rubriblastos. Na necropsia, além de evidências de anemia, havia esplenomegalia e linfadenomegalia. O diagnóstico de LMA M6B foi confirmado histologicamente e o aumento do baço e dos linfonodos foi decorrente de metastatização.
RESUMO
Acute erythroid leukemia (AML M6) is a hematopoietic neoplasm frequently described in cats and mice, rarely in other animal species. This report describes a case of AML M6 in a yearling Thoroughbred filly. Clinically the horse presented marked pale mucous membranes and exercise intolerance. In addition, the owner and referring veterinarian reported a 30-day history of progressive weight loss. The CBC revealed severe anemia and leukopenia by neutropenia. Cytology evaluation obtained from bone marrow fine needle aspirates evidenced inversion of the myeloid: erythroid ratio (0.2), with 48% of the nucleated cells corresponding to rubriblasts. In addition to the gross evidence of anemia, necropsy findings consisted of splenomegaly and lymphadenomegaly. The diagnosis of AML M6B was confirmed histologically due to splenomegaly and lymphadenomegaly, secondary to neoplastic metastasization.(AU)
Leucemia eritroide aguda (LMA M6) é um neoplasia hematopoiética descrita com frequência em gatos e camundongos, mas raramente nas demais espécies de animais. Esse relato descreve um caso dessa doença em um equino, fêmea, Puro Sangue Inglês de um ano de idade. Clinicamente, o equino apresentou acentuada palidez das mucosas, intolerância ao exercício e o proprietário relatava emagrecimento progressivo. No hemograma, foi observada anemia grave e leucopenia por neutropenia. No mielograma, havia inversão da relação mieloide:eritroide (0,2) e 48% das células nucleadas da medula óssea correspondiam a rubriblastos. Na necropsia, além de evidências de anemia, havia esplenomegalia e linfadenomegalia. O diagnóstico de LMA M6B foi confirmado histologicamente e o aumento do baço e dos linfonodos foi decorrente de metastatização.(AU)
Assuntos
Animais , Feminino , Doenças dos Cavalos , Leucemia Eritroblástica Aguda/diagnóstico , Leucemia Eritroblástica Aguda/veterinária , Células Eritroides/patologiaRESUMO
INTRODUCTION: This study aimed to verify the association between the JAK2 46/1 haplotype (V617F positive) and some hematological parameters in BCR-ABL-negative chronic myeloproliferative neoplasms (cMPNs) in our population. METHODS: The blood samples obtained from the patients with cMPN were genotyped for the JAK2 V617F mutation and JAK2 rs10974944 SNP screening using a PCR-RFLP assay. RESULTS: The JAK2 V617F mutation was detected in 80.15% of patients. The G variant of rs10974944 was more frequent in all MPNs, especially those that were JAK2 V617F positive, than in the control population. We also compared the 46/1 haplotype status in each MPN disease entity, polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), and MPNu with controls. The G allele frequency relative to controls was significantly enriched in patients with PV and ET, but not in those with PMF and MPNu. PV and ET patients especially, all of whom had the JAK2 V617F mutation, showed significant excess of the G allele. The frequency of JAK2 V617F mutation was associated with elevated hematological parameters, but when we analyze the occurrence of the mutation and the presence of the G allele, just the high hemoglobin was significantly. CONCLUSION: In agreement with previous reports, JAK2 46/1 haplotype for JAK2 V617F was associated with cMPN positive in Brazilian patients.